# LP-184

Source: https://onco.cc/drugs/lp-184/  
OnCo record `lp-184` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma.

## Summary

LP-184 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Lantern Pharma Inc., in triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: LP-184
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of LP-184: https://clinicaltrials.gov/search?intr=LP-184

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- trials: [Study of LP-184 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05933265/)

---
JSON: https://onco.cc/api/v1/entities/lp-184.json